Destiny Pharma (LSE:DEST)
Historical Stock Chart

From May 2022 to May 2024

TIDMDEST

RNS Number : 4885I

Destiny Pharma PLC

02 December 2022

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Director Disclosure

Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, makes the following disclosure in relation to Nick Rodgers, Chairman of the Company, pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

Productiv Ltd, a company of which Nick Rodgers was part time director, was placed into liquidation on 18 November 2022. At the time of liquidation, Productiv had an estimated deficit to creditors of approximately GBP250,000.

For further information, please contact:

 
 Destiny Pharma plc                                             +44 (0)1273 704 440 
  Neil Clark, CEO                                     pressoffice@destinypharma.com 
  Shaun Claydon, CFO 
 finnCap Ltd (Nominated Adviser and Joint 
  Broker) 
  Geoff Nash / Abigail Kelly / George Dollemore, 
  Corporate Finance 
  Alice Lane / Nigel Birks / Harriet Ward, 
  ECM                                                          +44 (0) 207 220 0500 
 Shore Capital (Joint Broker) 
  Daniel Bush / James Thomas / Lucy Bowden                     +44 (0) 20 7408 4090 
 Optimum Strategic Communications                              +44 (0) 208 078 4357 
  Mary Clark / Nick Bastin / Manel Mateus            DestinyPharma@optimumcomms.com 
 MC Services AG 
  Anne Hennecke / Andreas Burckhardt                              +49-211-529252-12 
 Stern IR - US                                                      +1-212-362-1200 
  Janhavi Mohite                                         Janhavi.Mohite@sternir.com 
 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

   For further information on the company, please visit   https://www.destinypharma.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCDZMGZDZDGZZM

(END) Dow Jones Newswires

December 02, 2022 09:48 ET (14:48 GMT)